Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Blausiegel Enoxaparin vs Clexane in Chronic Renal Disease Patients on Hemodialysis
NCT00673426Phase 3Completed
- Sponsor
- Azidus Laboratories Limited
- Start
- Jan 2008
- Primary completion
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enoxaparin in chronic kidney disease (CKD) (2 arms), sponsored by Azidus Laboratories Limited. Primary endpoint: Safety of using the drug evaluated by monitoring events. Started Jan 2008; status: completed.
02
Drugs
enoxaparin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT00673426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673426.